JPM Wrap-up: XtalPi Shines at Global Conference, AI + Robotics Redefining Drug Discovery Paradigm

Recently, the 44th J.P. Morgan Healthcare Conference concluded successfully in San Francisco, USA. As the "barometer" and "top stage" of the global biopharmaceutical industry, this conference brought together top pharmaceutical companies, investment institutions, and innovative enterprises worldwide, focusing on six core fields: biotechnology, biopharmaceuticals, AI + medicine, and more.

As a leading company in the AI pharmaceuticals field, XtalPi was invited to attend this grand event. Dr. Ma Jian, Co-founder and CEO of the company, delivered a keynote speech during the conference, providing an in-depth interpretation of how to reshape the new paradigm of drug research and development by integrating AI with robotics.

AI + Robotics Reconstructing the Logic of Drug Development

Currently, the global pharmaceutical industry is rapidly embracing AI transformation, with Chinese companies demonstrating strong innovative vitality in the global biopharmaceutical field. XtalPiBy integrating cutting-edge technologies such as quantum physics, artificial intelligence, and robotics, we steadily strengthen our technical foundation and continuously drive the paradigm shift in drug discovery.

XtalPi Actively Expands with a Dual-Drive Strategy: Focusing on Unmet Clinical Needs to Build High-Value Drug Assets, Collaborating with Partners to Overcome R&D Challenges; Meanwhile, Deepening the Construction of AI and Robotic Intelligent Experimentation Platforms, Continuously Exploring Their Application Potential Across Multiple Industries, with the Intelligent Platform Extending to Petrochemicals, New Materials, and Other Fields.

The company's collaborative pipeline has also yielded fruitful results: SIGX1094, the world’s first targeted drug for diffuse gastric cancer developed by its incubated company Signet Therapeutics, has entered Phase I clinical trials and received2025 US Galien Award NominationsDual Designation of Orphan Drug and Fast Track by the U.S. FDA，In addition, the pan-TEAD inhibitor SIGX2649 has completed preclinical studies and is about to initiate clinical applications.；Lake Bio's ultra-low-dose CAR-T therapy has shown outstanding performance in IIT clinical research for hematological tumors and autoimmune diseases, with excellent safety, and the therapy is being expanded to the solid tumor field.Xili Tech'sRNA-Targeting Small Molecule Pipeline，RTX-117 for CMT successfully achieves "dual filing and dual approval" in China and the US, receiving IND clinical approval from China's NMPA and the US FDA;Intelligent Engine Biotech's Next-Generation PRMT5 Inhibitor PEP08It has also received clinical trial approvals in multiple regions, including Australia and Taiwan, China, and is about to initiate Phase I clinical trials.

Dr. Ma Jian shared profound insights into the future development of AI in his speech: AI has gone through a decade of exploration in "understanding human language," and the core of the next decade is to endow it with "natural language" understanding and logical reasoning abilities akin to those of scientists. However, this cannot be achieved without the support of high-quality data — traditional manual data collection suffers from pain points such as the lack of negative samples and insufficient reliability, making it difficult to meet the rigorous demands of scientific research. To address this, XtalPi has builtHigh-Quality Data Infrastructure Integrating AI, Robotic Experiments, and Simulation Computing, forming a closed-loop of "data collection - production - algorithm training - experimental validation - data feedback" to provide high-quality datasets and algorithmic model support for global biopharmaceutical R&D, thereby solidifying the foundation for breakthroughs in cutting-edge technologies with a robust data infrastructure.

AI Empowers New Possibilities in Molecular Glue Research and Development

During the conference, XtalPi also intensively organized and participated in multiple industry exchange events, efficiently connecting with global industry partners. Among these, Dr. Wang Yuan, Head of the Small Molecule Drug Discovery Platform, delivered a speech at the Biotech Showcase™ 2026 Healthcare Investor Conference, systematically introducing the core advantages of XtalPi's molecular glue platform. He shared how AI and robotics can overcome challenges in molecular glue discovery, driving R&D in this field from "empiricism" towards "rational design."

Molecular Glue as a New GenerationProximity-induced therapy, with core advantages such as degrading pathogenic proteins and targeting undruggable molecules, holds significant clinical and commercial value.The value has been fully validated, but the industry has long faced pain points such as reliance on random screening and difficulty in precise design. XtalPi, leveraging physics-based computational simulations, high-throughput screening, and proprietary predictive tools, combined with an AI-driven robotic laboratory, is committed to overcoming core technical challenges in molecular glue research and development.

XtalPiSenior Vice PresidentWang Yuan

Global Collaborative Innovation

Link Top Minds, Build an Open Innovation Ecosystem Together

The depth of innovation stems from the breadth of collaboration and the richness of the ecosystem. At this year's JPM conference, we showcased our open innovation network built through collaborations with top global universities and a diversified Portfolio layout — deeply engaging with institutions like Harvard, MIT, and Stanford to incubate innovative platforms across cutting-edge fields such as AI research tools, protein engineering, RNA targeting, and epigenetics. Some core achievements were highlighted at the exhibition, drawing significant attention from the industry.

In the external innovation ecosystem, MorphMind's no-code AI research Agent platform has empowered more than 20 research laboratories, achieving full-process intelligence in target discovery, ADMET prediction, and more. Foundry Bio, with its AI-designed protein technology, has made breakthrough progress in regenerative medicine, hair activation, and other fields, with related pipelines soon entering productization. Additionally, CytoCan’s tumor-specific immune cytokine platform, Jikang’s"Structured + AI"The GPCR antibody development platform, Alternative Bio's next-generation epigenetic target drug platform, and Xellar's high-throughput screening platform that integrates organ-on-a-chip with AI have all become the focus of the exhibition due to their differentiated technical barriers and solid R&D data.

At the same time, the company's internal innovation platform continues to make efforts:AI Peptide Drug Discovery Platform PepiX has made significant progress in brain and ocular delivery, as well as cyclic peptide design and screening, enabling the platform to screen pM-level cyclic peptide molecules within months for a project; AI Small Nucleic Acid Design Platform XtalSilence can design innovative siRNA molecules with significantly reduced off-target risks through AI iteration; X-Buddy, the personal research assistant based on LLM and multi-agent systems, along with the PBPK simulation platform MirraXinic, provide efficient tool support throughout the entire R&D process.

From collaborative basic research in global universities, to the technical transformation and implementation of Portfolio companies, to the core competency accumulation within internal platforms, we are driving innovation with a "collaborative openness + deep technology" dual approach, building an innovative ecosystem that covers the entire drug R&D chain, continuously delivering breakthrough solutions for unmet clinical needs.

Founder & CEO of XtalPi Ecosystem Company Morphmind, Jack DingXtalPi Ecosystem Poster Display (Swipe left and right for more)

At this year's JPM, XtalPi showcased its technological expertise, strategic layout, and forward-looking vision in the AI + robotics drug discovery field through various formats. This not only deepened its collaborative connections with global industry partners but also conveyed to the world the innovative strength of China's AI-driven pharmaceutical enterprises.